Invizyne Technologies Files Registration Statement with SEC for Public Offering
Invizyne Technologies, Inc., a leading designer of enzyme-based biomanufacturing systems, has announced that it has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) for a public offering of its common stock. The offering will consist of 4,300,000 shares of common stock priced at $4.00 per share, resulting in gross proceeds of $17.2 million.
Listing and Underwriting Information
Invizyne has applied to list its common shares on The Nasdaq Stock Market under the ticker symbol “IZTC.” Public Ventures, LLC will serve as the underwriter and sole book manager for the offering, while Digital Offering, LLC will act as the qualified independent underwriter. Public Ventures, LLC is a subsidiary of MDB Capital Holdings, LLC, the parent company of Invizyne.
Allocation of Shares
In allocating the shares to be sold, Public Ventures, LLC intends to prioritize holders of MDB Class A Shares, followed by other beneficial shareholders of MDB and Invizyne. If there are remaining shares after these groups have made their purchases, the shares will be sold to other individuals who have indicated their interest through their brokers or dealers.
It is important to note that the registration statement relating to these securities has been filed with the SEC, but it has not yet become effective. Therefore, the securities cannot be sold, and offers to buy them cannot be accepted until the registration statement becomes effective.
This press release emphasizes that it does not constitute an offer to sell or the solicitation of an offer to buy any securities. Additionally, there will be no sale of these securities in any state or jurisdiction where such sale would be deemed unlawful without prior registration or qualification under the securities laws of that state or jurisdiction.
Significant Growth and Expansion for Invizyne
Invizyne’s public offering is a significant step in the company’s growth and expansion plans. It will provide the necessary capital to support its continued development of enzyme-based biomanufacturing systems, which have gained traction in various industries. With its innovative technologies and strong market potential, Invizyne is poised to make a significant impact in the biomanufacturing sector.
Analyst comment
Positive news. The public offering of Invizyne Technologies’ common stock will provide $17.2 million in gross proceeds, supporting their growth and development plans for enzyme-based biomanufacturing systems. This will likely lead to increased investment and advancement in the biomanufacturing sector.
